Retinitis Pigmentosa Type 11 (RP11)
VP-001 Phase 1 trial
Trial Status: Recruiting
Location: United States
Contact For Participation: VP001@oraclinical.com
PYC is conducting a phase 1 open-label study of RP11 Patients who have a genetic mutation in the PRPF31 gene. The primary objective of the study is to assess the safety and tolerability of VP-001. Patients who participated in the RP11 Natural History Study are eligible to participate in this trial.
If you are interested in learning more about this clinical trial, visit clinicaltrials.gov for a list of active sites and contact the site’s study coordinator for more information.
Retinitis Pigmentosa Type 11 (RP11) Natural History Study
Trial Status: Enrolling
Location: United States, Western Australia
Contact For Participation: email@example.com
PYC is conducting a study to characterise the natural history the systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, or RP11.
This is a non-interventional trial with assessments that will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Results of this 4 year study will be utilised in conjunction of the VP-001 clinical trials to asses efficacy. If you are interested in learning more about this clinical trial, visit clinicaltrials.gov for a list of active sites and contact the site’s study coordinator for more information.
We believe in the importance of collaborating closely with patients, their families, patient advocacy organizations, physicians, researchers and regulatory authorities to help achieve our goals together. Treating physicians, patients and/or caregivers interested in learning more about PYC Therapeutics’ investigational product currently undergoing clinical studies can find more information at www.clinicaltrials.gov. General information, please contact firstname.lastname@example.org